Neutralizing antibody (NAb) testing using the cytopathic effect (CPE) assay to assess interferon beta treatment of multiple sclerosis

Record ID 32011000811
English
Authors' objectives:

Multiple sclerosis (MS) is a chronic disabling disease of the central nervous system in which the body's immune cells attack and destroy the myelin coating of nerve cells, a process known as demyelination. MS is believed to affect approximately 400,000 people in the United States, striking primarily between the ages of 20 and 50 years, and disproportionately affecting women. In patients who have MS, characteristic lesions can be seen on imaging studies of the brain and spinal cord. These lesions are believed to result when white blood cells migrate into the brain and initiate a series of events resulting in inflammation, demyelination, and plaque formation. Usual care for MS includes drugs that interfere with the overactive immune response such as corticosteroids and other immune-modifying drugs, in particular, interferon beta-1a. In some patients, the interferon is recognized as a foreign protein, triggering the formation of antibodies that bind to it and reduce or eliminate its therapeutic effect.

Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antibodies
  • Interferon-beta
  • Multiple Sclerosis
  • Neutralization Tests
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.